New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little?

American Society of Clinical Oncology Educational Book
Michael A SpinnerCatherine S Diefenbach

Abstract

Hodgkin lymphoma treatment continues to evolve as new means of assessing response to treatment, new appreciation of important risk factors, and more effective therapeutic agents become available. Treatment algorithms integrating functional imaging now provide the opportunity to modify therapy during its delivery, allowing adjustment of duration and intensity of chemotherapy and rationale identification of patients who may benefit from the addition of therapeutic irradiation. Novel agents, including the antibody drug conjugate brentuximab vedotin and checkpoint inhibitors such as nivolumab and pembrolizumab can improve the effectiveness of treatment while keeping toxicity within acceptable limits. Carefully designed clinical trials permit the identification of superior approaches in which efficacy is enhanced and toxicity minimized. Clinicians treating patients with Hodgkin lymphoma now have access to novel treatment approaches, which will require detailed assessment of each patient and careful discussion of the goals and risks of treatment at the time of planning primary treatment, again during delivery of that treatment as data indicating ongoing effectiveness become available, at the conclusion of initial intervention, and, w...Continue Reading

References

Nov 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T A ListerM Tubiana
Mar 21, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M LoefflerP Wiernik
Jun 13, 2003·The New England Journal of Medicine·Volker DiehlUNKNOWN German Hodgkin's Lymphoma Study Group
Jun 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gianni BonadonnaPinuccia Valagussa
Sep 21, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J FranklinJ Yahalom
Jul 18, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A AvigdorA Polliack
Aug 12, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marie L De BruinFlora E van Leeuwen
Aug 18, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hans Theodor EichAndreas Engert
Sep 8, 2010·The New England Journal of Medicine·Andreas EngertVolker Diehl
Dec 21, 2010·British Journal of Haematology·Andrea GallaminiUNKNOWN Gruppo Italiano Terapie Innovative nei Linfomi (GITIL)
Dec 14, 2011·The New England Journal of Medicine·Ralph M MeyerUNKNOWN Eastern Cooperative Oncology Group
Jan 19, 2012·International Journal of Radiation Oncology, Biology, Physics·Matthew KoshyYoung Kwok
Jan 25, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bastian von TresckowAndreas Engert
Jan 25, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael R GreenMargaret A Shipp
Mar 29, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anas YounesRobert Chen
Aug 8, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alden A MocciaLaurie H Sehn
Dec 12, 2012·American Journal of Hematology·Maike SauerElke Pogge von Strandmann
Mar 1, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Catherine Diefenbach, Christian Steidl
Mar 22, 2013·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Alberto BiggiSally F Barrington
Jun 25, 2013·International Journal of Radiation Oncology, Biology, Physics·Lena SpechtUNKNOWN ILROG
Oct 15, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A E HayUNKNOWN Conducted by the NCIC Clinical Trials Group (Canada) and German Hodgkin Study Group (GHSG)
Oct 24, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B KlimmP Borchmann
Jun 20, 2014·Current Hematologic Malignancy Reports·Francesca Montanari, Catherine Diefenbach
Dec 9, 2014·The New England Journal of Medicine·Stephen M AnsellPhilippe Armand
Jan 15, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Adam J OlszewskiJorge J Castillo
Feb 24, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P GanesanT G Sagar
Apr 23, 2015·The New England Journal of Medicine·John RadfordSally Barrington
Aug 19, 2015·International Journal of Radiation Oncology, Biology, Physics·Rahul R ParikhJoachim Yahalom
Dec 25, 2015·The New England Journal of Medicine·Michael SchaapveldFlora E van Leeuwen
Dec 30, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Francesco MerliMassimo Federico

❮ Previous
Next ❯

Citations

Jul 1, 2020·Annals of Hematology·Hans-Jochem Kolb, Christoph Schmid
Jun 28, 2021·Seminars in Diagnostic Pathology·Xiaoqiong WangAndres E Quesada

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.